Results 41 to 50 of about 35,545 (253)
FEBS Open Bio, EarlyView.The MRP4 transporter exports several drugs and signaling molecules. Here, we identified key promoter elements regulating basal MRP4 expression. Using reporter assays, we defined a conserved region with essential Sp1 and contributory Ets sites, which controlled basal MRP4 expression.
Debora Singer +7 more
wiley +1 more source
Use of sodium glucose co‐transporter 2 inhibitors in acute heart failure: a practical guidance
ESC Heart Failure, 2022 Aims Heart failure (HF) is the most frequent cause of hospital admission among patients 65 years or older. Patients hospitalized for acutely decompensated chronic HF and ‘de novo’ acute heart failure (AHF) continue to experience unacceptably high post ...
João Pedro Ferreira +4 more
doaj +1 more source
A case report of euglycemic ketoacidosis due to dapagliflozin treatment
Turkish Journal of Internal Medicine, 2021 Diabetic ketoacidosis (DKA) is a leading cause of mortality and morbidity in type 2 diabetic patients. Sodium-glucose co-transporter (SGLT-2) inhibitors are a new antidiabetic treatment class that increases the renal excretion of glucose.
Murat Çalapkulu +4 more
doaj +1 more source
Sodium-glucose co-transporter 2 inhibitors and erythrocytosis: a review
British Journal of Diabetes, 2022 Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a class of anti-hyperglycaemic agents widely used in the treatment of type 2 diabetes mellitus (T2DM). They function by reducing renal glucose reabsorption and thereby promote urinary glucose excretion, resulting in improvement in glycaemic control. In large-scale clinical trials, SGLT2i have been
Najeeb Shah +5 more
openaire +1 more source
FEBS Open Bio, EarlyView.In normal (nontolerant) cells, CD14 is crucial for both LPS uptake and LPS signaling. In LPS‐tolerant cells, in which LPS‐induced TNF‐α and IFN‐β production is suppressed, there is a dramatic increase in surface CD14 expression. The overexpressed CD14 in LPS‐tolerant cells is responsible for the enhanced LPS uptake without inducing pro‐inflammatory ...
Saeka Nishihara +3 more
wiley +1 more source
ESC Heart Failure, 2022 Aims Recent trials have evaluated sodium–glucose co‐transporter 2 inhibitors in patients with heart failure (HF). We sought to assess the robustness of findings from these trials using the fragility index (FI).
Muhammad Shariq Usman +9 more
doaj +1 more source
Cardiology Journal, 2023 Several mechanisms have been suggested to explain positive cardiovascular effects observed in studies with sodium-glucose co-transporter 2 (SGLT2) inhibitors.
Jacek Kubica +24 more
doaj +1 more source
Evaluating the involvement of autolysosomes in the nuclear translocation of fluorescent proteins
FEBS Open Bio, EarlyView.Endogenously expressed fluorescent proteins can be degraded by autophagy and transported to cell nuclei via the nuclear pore complex. But in some cell lines, for example, HeLa cells which are positive for immunoreactivity of a receptor ligand, such as UCN I, in cell nuclei, fusion of autolysosome with the nuclear envelope is involved in the nuclear ...
Keiichi Ikeda
wiley +1 more source
Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary
Frontiers in Cardiovascular Medicine, 2022 A new therapeutic class of oral agents firstly used for the treatment of type 2 diabetes mellitus is represented by gliflozines or sodium-glucose co-transporter 2 (SGLT2) inhibitors.
Annamaria Mascolo +17 more
doaj +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated significant weight‐reducing effects and may offer benefits in idiopathic intracranial hypertension (IIH); however, recent concerns about the risk of non‐arteritic anterior ischemic optic neuropathy (NAION) have emerged.
Faisal A. Al‐Harbi +9 more
wiley +1 more source